At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02565 PEGBIO CO-B
Not Yet Opened 04-16 16:08:12
43.000
-0.900
-2.05%
High44.420
Low41.280
Vol1.55M
Open44.420
D1 Closing43.900
Amplitude7.15%
Mkt Cap16.81B
Tradable Cap12.21B
Total Shares391.00M
T/O65.21M
T/O Rate0.54%
Tradable Shares284.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
PegBio Wins China Nod for Hong Kong Share Full Circulation
PegBio Co Ltd is a China-based company principally engaged in the discovery and development of innovative therapies. The Company's main product PB-119, is a self-developed, near-commercialized, long-acting glucagonlike peptide 1 (GLP-1, a peptide hormone that decreases blood sugar levels) receptor agonist. The Company's product candidates include PB-718, PB-1902, PB-722, PB-2301 and PB-2309. The Company's products are mainly used to treat chronic and metabolic diseases, including type 2 diabetes mellitus (T2DM, also known as type 2 diabetes), obesity, non-alcoholic steatohepatitis (NASH), opioid-induced constipation (OIC, a gastrointestinal disorder induced by the usage of opioid drugs) and congenital hyperinsulinemia (a rare endocrine disease whose patients experience constant hypoglycemia).